# US 2013/0259958 A1 · Herbal compositions for the prevention or treatment of benign prostatic hyperplasia and related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259958 A1
- Document ID: US20130259958A1
- Status: Published application
- Kind: A1
- Application number: 13/800,735
- Filed: 2013-03-13
- Published: 2013-10-03
- Earliest claimed: 2012-04-02
- Assignees: Seipel Group Pty Ltd
- Inventors: Tracey Anne Seipel
- Web page: https://patentgrep.com/patent/US20130259958A1

## CPC

- A61K 36/889: Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
- A61K 36/11: Pteridophyta or Filicophyta (ferns)
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61P 13/08: of the prostate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided in one embodiment is an herbal composition for the prevention or treatment of disorders of the prostate, for example, benign prostatic hyperplasia (BPH), prostatitis, and prostatic intraepithelial neoplasia, and for overactive bladder (OAB), urinary incontinence (UI), nocturia, poor urinary stream, and straining to urinate associated with these prostate disorders. Specifically one embodiment provides compositions that contain Crateva nurvala, Equisetum arvense, Lindera aggregata, and Serenoa repens, and methods of use thereof.

## Claims

### Claim 1

An herb-containing composition, comprising:
(i) a Crateva nurvala extract preparation;
(ii) an Equisetum arvense extract preparation;
(iii) a Lindera aggregata extract preparation; and
(iv) a Serenoa repens extract preparation, wherein the herb-containing composition is formulated as an oral dosage unit.

### Claim 2 (depends on 1)

The herb-containing composition of claim 1, wherein the Crateva nurvala preparation is present at a concentration from about 1 g to about 18 g dry weight equivalents per oral dosage unit, the Equisetum arvense extract preparation is present at a concentration from about 750 mg to about 12 g dry weight equivalents per oral dosage unit, the Lindera aggregata extract preparation is present at a concentration from about 750 mg to about 12 g dry weight equivalents per oral dosage unit, and the Serenoa repens preparation is present at a concentration from about 1 g to about 18 g dry weight equivalents per oral dosage unit.

### Claim 3 (depends on 1)

The herb-containing composition of claim 1, wherein the Crateva nurvala preparation is present at a concentration from about 3 g to about 12 g dry weight equivalents per oral dosage unit, the Equisetum arvense extract preparation is present at a concentration from about 1.5 g to about 6 g dry weight equivalents per oral dosage unit, the Lindera aggregata extract preparation is present at a concentration from about 1.5 g to about 6 g dry weight equivalents per oral dosage unit, and the Serenoa repens preparation is present at a concentration from about 1.5 g to about 12 g dry weight equivalents per oral dosage unit.

### Claim 4 (depends on 1)

The herb-containing composition of claim 1, wherein the Crateva nurvala preparation is present at a concentration from about 4 g to about 8 g dry weight equivalents per oral dosage unit, the Equisetum arvense extract preparation is present at a concentration from about 2 g to about 4 g dry weight equivalents per oral dosage unit, the Lindera aggregata extract preparation is present at a concentration from about 2 g to about 4 g dry weight equivalents per oral dosage unit, and the Serenoa repens preparation is present at a concentration from about 3 g to about 8 g dry weight equivalents per oral dosage unit.

### Claim 5 (depends on 1)

The herb-containing composition of claim 1, wherein the composition has at least one of the following:
(i) the Crateva nurvala extract preparation is a stem/bark extract preparation;
(ii) the Equisetum arvense extract preparation is a stem extract preparation;
(iii) the Lindera aggregata extract preparation is a root extract preparation; and
(iv) the Serenoa repens extract preparation is a leave/berry extract preparation.

### Claim 6 (depends on 1)

The herb-containing composition of claim 1, wherein the herb-containing composition is formulated in a dry delivery system.

### Claim 7 (depends on 1)

The herb-containing composition of claim 1, wherein the herb-containing composition is formulated in a liquid delivery system.

### Claim 8 (depends on 1)

The herb-containing composition of claim 1, wherein the herb-containing composition is formulated in a controlled-release vehicle.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the herb-containing composition of claim 1 and a pharmaceutically-acceptable carrier.

### Claim 10

An herb-containing composition, comprising:
(i) a Crateva nurvala stem/bark extract preparation present;
(ii) an Equisetum arvense stem extract preparation;
(iii) a Lindera aggregata root extract preparation; and
(iv) a Serenoa repens leave/berry extract preparation,
wherein the herb-containing composition is formulated as an oral dosage unit, and wherein the Equisetum arvense stem extract preparation and the Lindera aggregata root extract preparation are present at the same concentration.

### Claim 11 (depends on 10)

The herb-containing composition of claim 10, wherein the Crateva nurvala stem/bark preparation is present at a concentration of at least about 1,500 mg dry weight equivalents per oral dosage unit.

### Claim 12 (depends on 10)

The herb-containing composition of claim 10, wherein the Equisetum arvense stem extract preparation and the Lindera aggregata root extract preparation are present at a concentration of at least about 1,000 mg dry weight equivalents per oral dosage unit

### Claim 13 (depends on 10)

The herb-containing composition of claim 10, wherein the Serenoa repens leave/berry extract preparation is present at a concentration of at least about 3,200 mg dry weight equivalents per oral dosage unit.

### Claim 14 (depends on 10)

A pharmaceutical composition comprising the herb-containing composition of claim 10 and a pharmaceutically-acceptable carrier.

### Claim 15 (depends on 10)

The herb-containing composition of claim 10, wherein the oral dosage unit is selected from the group consisting of: a tablet, dry powder, capsule, and caplet.

### Claim 16

A method for the prevention or treatment of the symptoms of Benign Prostate Hypertrophy (BPH), comprising: administering an herb-containing composition to a subject in need thereof, wherein the herb-containing composition comprises:
(i) a Crateva nurvala extract preparation;
(ii) an Equisetum arvense extract preparation;
(iii) a Lindera aggregata extract preparation; and
(iv) a Serenoa repens extract preparation, and wherein the herb-containing composition is formulated as an oral dosage unit.

### Claim 17 (depends on 16)

The method of claim 16, wherein the treatment results in a reduction in the frequency of urination after about two weeks.

### Claim 18 (depends on 16)

The method of claim 16, wherein the treatment results in a reduction in the frequency of urination after about one month.

### Claim 19 (depends on 16)

The method of claim 16, wherein, compared to a subject not administered the herb-containing composition, the treatment results in an improvement of at least one of:
(i) average daily frequency of urination;
(ii) average nightly frequency of urination; and
(iii) urinary urgency episodes.

### Claim 20 (depends on 16)

The method of claim 16, further comprising at least one of the following:
(i) extracting the Crateva nurvala preparation from Crateva nurvala stems and/or bark at an extract ratio of from about 25 to about 35;
(ii) extracting the Equisetum arvense extract preparation from Equisetum arvense stem at an extract ratio of about 10;
(iii) extracting the Lindera aggregata preparation from Lindera aggregata root at an extract ratio of about 10; and
(iv) extracting the Serenoa repens preparation from Serenoa repens leaves and/or berries at an extract ratio of about 10.
